ArticleWorld journal of surgical oncology2026
Prognostic impact of adjacent organ invasion on cancer-specific mortality in non-metastatic renal cell carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe increase in cancer-specific mortality (CSM) associated with pathologically confirmed adjacent organ invasion (pT4) in non-metastatic (M0) renal cell carcinoma (RCC), relative to limited local invasion (pT3) or no local invasion (pT2) with otherwise same patient and tumor characteristics, is unknown. We addressed this knowledge gap.
methodsWithin the Surveillance, Epidemiology, and End Results database (2004-2022), M0 RCC patients treated with radical nephrectomy were identified. Propensity score matching (PSM) was applied, and multivariable competing-risks regression (CRR) models were fitted. Additional sensitivity analyses were performed to evaluate the robustness of the primary findings.
resultsOf 27,859 patients, 666 (2.4%) were classified as pT4, 15,343 (55.1%) as pT3, and 11,850 (42.5%) as pT2. After PSM, CSM at 120 months was 63.0% in pT4 versus 43.2% in pT3 and 26.0% in pT2. In multivariable CRR models, pT4 was associated with 1.84-fold higher CSM compared with pT3 (p < 0.001) and 3.31-fold higher CSM compared with pT2 (p < 0.001). In sensitivity analyses restricted to patients with clear-cell RCC, patients diagnosed before approval of adjuvant systemic therapy, and patients without lymph node invasion, corresponding effect estimates ranged from 1.79 to 1.93 for the comparison with pT3 and from 2.96 to 3.47 for the comparison with pT2 (all p < 0.001).
conclusionIn M0 RCC, the presence of adjacent organ invasion (pT4) doubles the rate of CSM relative to pT3 and triples the rate of CSM relative to pT2 when all other tumor and patient characteristics are held constant. These findings quantify the very aggressive nature of pT4 independent of other tumor and patient characteristics and thereby validate contemporary T staging. Accordingly, more frequent follow-up and prioritization of pT4 patients for discussions regarding adjuvant systemic therapy may be warranted compared with their pT3 and pT2 counterparts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.